WSCM
BLRX

Wellington Shields Capital Management’s BioLineRX BLRX Stock Holding History

Wellington Shields Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17
Closed -$11K – 318
2016
Q3 		$11K Buy
+17
New +$9.06K ﹤0.01% 310

Other funds holding BLRX

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Wellington Shields Capital Management's BLRX Position: Q4 2016 in Review

Wellington Shields Capital Management sold out of BioLineRX (BLRX) in Q4 2016, closing a stake of 17 shares — an estimated $11K sold.

Wellington Shields Capital Management first reported a position in BLRX in Q3 2016 and held it in 1 quarter. The position peaked at $11K in Q3 2016. 22 funds tracked by Wall St. Rank hold BLRX as of Q4 2016.

  • Wellington Shields Capital Management reported no remaining BioLineRX position as of Q4 2016 after selling out during the quarter.
  • Wellington Shields Capital Management sold 17 BioLineRX shares in Q4 2016, an estimated $11K.
  • Wellington Shields Capital Management first reported a position in BioLineRX in Q3 2016 and held it in 1 quarter.
  • Wellington Shields Capital Management's BioLineRX position peaked at $11K in Q3 2016.
  • 22 funds tracked by Wall St. Rank held BioLineRX as of Q4 2016.

Based on Wellington Shields Capital Management's 13F filing for Q4 2016, filed 2 Feb 2017.